Experts in Excipients

Article

MEGGLE Excipients & Technology is a manufacturer of lactose for the pharmaceutical industry. With manufacturing facilities in Europe and US, MEGGLE offers a broad product portfolio of lactose excipients.

Experts in Excipients

MEGGLE Excipients & Technology is a global leader in the manufacture of lactose for the pharmaceutical industry.  Supporting supply chain security with manufacturing facilities in Europe and North America, MEGGLE offers a broad product portfolio of lactose excipients, co-processed technologies and excipient contract manufacturing. 

MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture.  Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage forms. 

As a family owned, German company, MEGGLE has proudly produced quality products for consumers and industry for four generations.

MEGGLE Excipients & Technologies serves the pharmaceutical and biotechnology markets with a global network of offices and authorized agents. As an innovator in co-processed technology, MEGGLE also provides contract manufacturing services to several other global excipient companies.

Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner by large and small pharmaceutical product manufacturers.          

MEGGLE Excipients & Technologies excipient products:

  • Lactose monohydrate

  • Anhydrous Lactose

  • Co-Processed Excipients

  • Lactose for Inhalation

  • Lactose for lyophilization and parenteral applications

  • Custom lactose products

Company name:  Molkerei MEGGLE Wasserburg GmbH & Co. KG
Website: www.meggle-pharma.deE-mail: service.pharma@meggle.de

 

Recent Videos
Roger Viney, PhD, chief commercial officer for ICE Pharma
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Related Content